TDMS Study 96020-01 Pathology Tables
NTP Experiment-Test: 96020-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: CHRONIC WITH AVERAGE SEVERITY GRADES[b] Date: 03/03/04
Route: GAVAGE TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153) Time: 10:11:30
FINAL #1
Facility: Battelle Columbus Laboratory
Chemical CAS #: TEFBINARYMIX
Lock Date: 03/27/02
Cage Range: All
Reasons For Removal: 25018 Dosing Accident 25019 Moribund Sacrifice
25020 Natural Death 25021 Terminal Sacrifice
Removal Date Range: All
Treatment Groups: Include 001 0 NG / 0 UG
Include 002 10 NG / 10 UG
Include 003 100 NG /100 UG
Include 005 300 NG /300 UG
Include 007 1000 NG/1000 UG
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 1
NTP Experiment-Test: 96020-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: CHRONIC WITH AVERAGE SEVERITY GRADES[b] Date: 03/03/04
Route: GAVAGE TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153) Time: 10:11:30
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 0 NG / 10 NG / 100 NG / 300 NG / 1000 NG/
0 UG 10 UG 100 UG 300 UG 1000 UG
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially In Study 98 86 98 98 98
Early Deaths
Moribund Sacrifice 22 19 24 19 20
Natural Death 8 12 6 10 7
Dosing Accident 1 1 1 2
Survivors
Terminal Sacrifice 22 21 22 24 24
Animals Examined Microscopically 53 53 53 53 53
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Esophagus (53) (53) (52) (53) (52)
Cyst 1 [3.0]
Perforation 1 2
Muscularis, Inflammation 3 [1.3] 1 [3.0] 1 [2.0] 3 [1.3] 3 [2.0]
Periesophageal Tissue, Hemorrhage 1 [3.0]
Periesophageal Tissue, Inflammation 1 [4.0] 1 [3.0]
Intestine Large, Colon (53) (53) (53) (52) (49)
Hyperplasia, Lymphoid 1 [2.0]
Parasite Metazoan 2
Intestine Large, Rectum (53) (53) (53) (53) (50)
Metaplasia, Squamous 1 [3.0]
Parasite Metazoan 2 1 3
Intestine Large, Cecum (53) (53) (53) (52) (49)
Mineralization 1 [3.0]
Intestine Small, Jejunum (53) (53) (52) (52) (49)
Hyperplasia, Lymphoid 1 [2.0] 2 [3.5] 1 [3.0]
Ulcer 1 [4.0]
Intestine Small, Ileum (53) (53) (52) (52) (49)
Hyperplasia, Lymphoid 1 [2.0]
Liver (53) (53) (52) (52) (51)
Angiectasis 3 [1.7] 1 [1.0] 1 [1.0] 2 [2.0] 5 [2.2]
Basophilic Focus 9 7 8 2 3
Basophilic Focus, Multiple 13 15 6 1 3
Cholangiofibrosis 1 [1.0] 7 [2.0] 39 [3.2]
Clear Cell Focus 3 2 2 3 1
Clear Cell Focus, Multiple 6 1 1
Eosinophilic Focus 7 8 4 7 1
Eosinophilic Focus, Multiple 7 8 26 33 17
Fatty Change, Diffuse 3 [1.7] 1 [1.0] 9 [1.7] 31 [1.5] 38 [1.6]
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 2
NTP Experiment-Test: 96020-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: CHRONIC WITH AVERAGE SEVERITY GRADES[b] Date: 03/03/04
Route: GAVAGE TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153) Time: 10:11:30
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 0 NG / 10 NG / 100 NG / 300 NG / 1000 NG/
0 UG 10 UG 100 UG 300 UG 1000 UG
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - CONT
Fatty Change, Focal 3 [1.0] 4 [1.0] 7 [1.1] 1 [2.0] 12 [1.9]
Hematopoietic Cell Proliferation 27 [1.2] 29 [1.0] 30 [1.1] 19 [1.1] 11 [1.0]
Hepatodiaphragmatic Nodule 2
Hyperplasia, Nodular 2 24 42
Inflammation 44 [1.1] 41 [1.0] 46 [1.1] 48 [1.2] 46 [1.5]
Metaplasia 1 [1.0]
Mixed Cell Focus 7 3 4 2 1
Mixed Cell Focus, Multiple 19 19 26 24 2
Necrosis 4 [1.8] 8 [2.0] 5 [2.0] 4 [1.0] 20 [2.3]
Pigmentation 2 [1.0] 5 [1.2] 38 [1.3] 50 [1.9] 50 [2.0]
Toxic Hepatopathy 2 [1.0] 34 [1.2] 48 [2.0] 49 [3.5]
Bile Duct, Cyst 4 [2.3] 3 [2.3] 1 [2.0] 5 [2.4] 23 [2.4]
Bile Duct, Dilatation 1 [4.0]
Bile Duct, Fibrosis 1 [1.0] 3 [1.0] 3 [1.0] 4 [1.0]
Bile Duct, Hyperplasia 8 [1.3] 2 [1.5] 9 [1.6] 29 [1.4] 46 [2.0]
Centrilobular, Degeneration 5 [1.8] 7 [2.0] 2 [2.5] 4 [1.5] 3 [2.3]
Centrilobular, Fibrosis 1 [1.0] 1 [2.0]
Hepatocyte, Hypertrophy 1 [1.0] 7 [1.0] 17 [1.4] 33 [2.1] 50 [3.3]
Hepatocyte, Multinucleated 14 [1.4] 46 [1.6] 48 [1.9]
Oval Cell, Hyperplasia 2 [1.0] 2 [1.0] 15 [1.3] 39 [1.6] 46 [2.9]
Portal, Fibrosis 7 [1.4] 34 [2.3]
Serosa, Inflammation, Chronic Active 1 [3.0]
Mesentery (47) (47) (46) (47) (42)
Artery, Inflammation, Chronic Active 1 [1.0] 1 [1.0] 1 [2.0] 2 [2.5] 4 [2.5]
Fat, Necrosis 2 [3.0] 2 [2.5] 1 [3.0]
Oral Mucosa (12) (11) (25) (30) (36)
Gingival, Hyperplasia, Squamous 8 [1.3] 8 [1.0] 18 [1.6] 22 [1.6] 24 [1.8]
Pharyngeal, Inflammation 1 [3.0]
Pancreas (53) (53) (52) (52) (50)
Inflammation, Chronic Active 3 [1.3] 3 [1.3] 1 [1.0] 4 [1.8]
Acinus, Atrophy 2 [1.5] 1 [2.0] 1 [1.0] 8 [1.6]
Acinus, Hyperplasia 2 [1.5] 1 [3.0]
Acinus, Vacuolization Cytoplasmic 7 [1.0] 40 [1.9]
Artery, Inflammation, Chronic Active 1 [3.0] 2 [2.5] 2 [3.0]
Duct, Dilatation 1 [3.0]
Salivary Glands (53) (51) (52) (50) (52)
Inflammation, Chronic Active 1 [3.0]
Stomach, Forestomach (53) (53) (52) (52) (51)
Hyperkeratosis 1 [3.0] 2 [2.0]
Hyperplasia, Squamous 1 [2.0] 1 [1.0] 2 [1.5] 7 [2.0] 8 [1.8]
Inflammation 1 [4.0] 1 [2.0]
Mineralization 1 [1.0] 1 [2.0]
Ulcer 1 [2.0] 2 [2.5] 1 [2.0]
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 3
NTP Experiment-Test: 96020-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: CHRONIC WITH AVERAGE SEVERITY GRADES[b] Date: 03/03/04
Route: GAVAGE TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153) Time: 10:11:30
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 0 NG / 10 NG / 100 NG / 300 NG / 1000 NG/
0 UG 10 UG 100 UG 300 UG 1000 UG
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - CONT
Stomach, Glandular (53) (53) (52) (52) (51)
Cyst 1 [1.0]
Ectopic Tissue 1 [4.0]
Erosion 1 [2.0] 2 [2.0]
Inflammation, Chronic Active 1 [4.0]
Mineralization 4 [1.5] 3 [1.3] 3 [1.0] 1 [2.0]
Ulcer 1 [3.0]
Tooth (23) (14) (33) (35) (31)
Peridontal Tissue, Inflammation 23 [1.2] 14 [1.6] 33 [1.2] 35 [1.5] 31 [1.5]
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Blood Vessel (53) (53) (52) (53) (52)
Aorta, Mineralization 1 [3.0]
Heart (53) (52) (52) (53) (52)
Cardiomyopathy 22 [1.0] 19 [1.1] 22 [1.0] 26 [1.1] 15 [1.0]
Fibrosis 1 [2.0]
Hemorrhage 1 [3.0]
Inflammation, Chronic Active 1 [4.0] 1 [3.0]
Thrombosis 1 [3.0]
Coronary Artery, Inflammation, Chronic Active 1 [1.0] 6 [1.2]
Pericardium, Necrosis 1 [3.0]
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (53) (53) (52) (52) (51)
Angiectasis 17 [1.4] 26 [1.7] 33 [1.6] 23 [1.7] 5 [1.8]
Atrophy 3 [3.0] 35 [2.6]
Degeneration, Cystic 13 [2.1] 12 [2.3] 13 [2.2] 14 [1.8] 16 [1.9]
Hematopoietic Cell Proliferation 1 [1.0]
Hyperplasia 11 [2.2] 18 [2.2] 23 [2.2] 25 [2.6] 18 [2.6]
Hypertrophy 47 [2.0] 38 [1.9] 44 [2.0] 41 [2.3] 32 [2.2]
Necrosis 1 [3.0] 1 [2.0]
Vacuolization Cytoplasmic 11 [1.5] 12 [1.6] 14 [1.2] 10 [1.4] 13 [1.6]
Adrenal Medulla (52) (53) (52) (52) (51)
Hyperplasia 15 [1.8] 13 [1.8] 14 [2.0] 13 [2.1] 3 [2.0]
Islets, Pancreatic (53) (53) (52) (52) (50)
Hyperplasia 1 [2.0]
Parathyroid Gland (45) (47) (46) (47) (46)
Hyperplasia 1 [2.0]
Pituitary Gland (53) (53) (53) (52) (52)
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 4
NTP Experiment-Test: 96020-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: CHRONIC WITH AVERAGE SEVERITY GRADES[b] Date: 03/03/04
Route: GAVAGE TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153) Time: 10:11:30
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 0 NG / 10 NG / 100 NG / 300 NG / 1000 NG/
0 UG 10 UG 100 UG 300 UG 1000 UG
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM - CONT
Angiectasis 17 [2.4] 20 [2.2] 15 [2.5] 17 [2.0] 1 [2.0]
Cyst 1 [2.0] 3 [2.7]
Cytoplasmic Alteration 3 [2.0]
Inflammation 1 [2.0]
Vacuolization Cytoplasmic 1 [2.0]
Pars Distalis, Hyperplasia 13 [2.4] 13 [2.5] 19 [2.5] 20 [2.5] 13 [2.0]
Pars Intermedia, Hyperplasia 2 [2.5]
Thyroid Gland (53) (53) (51) (52) (52)
C-Cell, Hyperplasia 15 [2.1] 19 [1.9] 22 [2.1] 12 [2.3] 15 [1.7]
Follicle, Cyst 2 [2.0]
Follicular Cell, Hypertrophy 14 [1.3] 17 [1.3] 34 [1.4] 35 [1.5] 42 [1.9]
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Clitoral Gland (53) (53) (53) (53) (50)
Inflammation 45 [1.8] 49 [1.8] 46 [1.7] 40 [1.4] 23 [1.1]
Duct, Cyst 38 [2.1] 40 [2.0] 48 [2.4] 43 [2.3] 43 [2.4]
Ovary (53) (53) (52) (52) (49)
Atrophy 45 [4.0] 44 [4.0] 45 [4.0] 43 [4.0] 16 [3.8]
Cyst 14 [2.4] 7 [2.1] 17 [2.2] 14 [2.6] 13 [2.5]
Inflammation, Chronic Active 1 [2.0] 1 [4.0] 1 [4.0]
Inflammation, Suppurative 1 [2.0]
Oviduct (1) (1) (2) (3)
Cyst 1 [2.0] 1 [3.0] 2 [2.0]
Inflammation, Chronic Active 1 [2.0] 3 [3.0]
Uterus (53) (53) (53) (52) (50)
Adenomyosis 1 [2.0] 1 [3.0]
Hemorrhage 1 [3.0]
Hyperplasia 1 [3.0]
Inflammation, Chronic Active 3 [2.3] 1 [3.0] 7 [2.6] 2 [3.5]
Inflammation, Suppurative 3 [1.3] 5 [1.8] 8 [1.8] 10 [1.6] 5 [2.0]
Metaplasia, Squamous 27 [2.0] 30 [2.2] 35 [2.1] 36 [2.9] 14 [2.4]
Ulcer 1 [3.0]
Endometrium, Hyperplasia, Cystic 28 [2.0] 23 [2.1] 34 [2.3] 18 [2.2] 12 [2.6]
Vagina (1) (1) (1) (1)
Inflammation 1 [3.0]
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 5
NTP Experiment-Test: 96020-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: CHRONIC WITH AVERAGE SEVERITY GRADES[b] Date: 03/03/04
Route: GAVAGE TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153) Time: 10:11:30
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 0 NG / 10 NG / 100 NG / 300 NG / 1000 NG/
0 UG 10 UG 100 UG 300 UG 1000 UG
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (53) (53) (53) (53) (53)
Atrophy 1 [3.0]
Degeneration 1 [3.0]
Hyperplasia 39 [3.2] 38 [3.0] 42 [2.9] 48 [2.8] 49 [2.7]
Lymph Node (4) (7) (2) (7) (14)
Angiectasis 1 [2.0] 1 [2.0]
Inguinal, Hyperplasia, Plasma Cell 1 [2.0]
Lumbar, Ectasia 4 [2.3] 4 [2.3] 1 [2.0]
Lumbar, Hemorrhage 2 [2.0]
Lumbar, Hyperplasia 1 [3.0]
Lumbar, Hyperplasia, Plasma Cell 4 [2.3] 1 [2.0]
Mediastinal, Ectasia 3 [2.0]
Mediastinal, Hemorrhage 1 [2.0] 2 [2.5]
Mediastinal, Hyperplasia, Histiocytic 1 [2.0] 1 [2.0] 3 [2.3]
Mediastinal, Hyperplasia, Lymphoid 1 [2.0]
Mediastinal, Hyperplasia, Plasma Cell 2 [2.0]
Pancreatic, Hyperplasia, Histiocytic 1 [2.0] 3 [2.7]
Pancreatic, Hyperplasia, Plasma Cell 1 [3.0]
Pancreatic, Pigmentation 1 [2.0] 1 [2.0]
Renal, Ectasia 1 [2.0] 1 [2.0] 1 [2.0] 1 [2.0]
Renal, Hemorrhage 1 [2.0]
Renal, Hyperplasia, Histiocytic 1 [2.0] 2 [2.5]
Renal, Hyperplasia, Lymphoid 1 [3.0]
Renal, Hyperplasia, Plasma Cell 1 [3.0] 1 [2.0]
Lymph Node, Mandibular (53) (51) (52) (50) (51)
Congestion 1 [3.0]
Ectasia 3 [2.0] 6 [1.7] 3 [1.7] 6 [2.3]
Hemorrhage 1 [2.0] 1 [2.0]
Hyperplasia, Lymphoid 1 [2.0] 2 [2.0] 3 [2.0] 2 [2.0] 5 [2.4]
Hyperplasia, Plasma Cell 37 [2.2] 37 [2.2] 40 [2.4] 36 [2.4] 31 [2.5]
Lymph Node, Mesenteric (53) (53) (52) (52) (49)
Hemorrhage 1 [2.0]
Hyperplasia, Histiocytic 1 [2.0] 2 [2.5]
Hyperplasia, Lymphoid 1 [4.0] 1 [3.0]
Inflammation, Chronic Active 1 [4.0]
Spleen (53) (53) (52) (52) (50)
Fibrosis 1 [3.0]
Hematopoietic Cell Proliferation 51 [2.2] 51 [2.1] 49 [2.2] 47 [2.0] 44 [1.8]
Hyperplasia 1 [2.0]
Pigmentation 47 [1.5] 46 [1.5] 43 [1.5] 51 [1.7] 46 [1.7]
Lymphoid Follicle, Atrophy 2 [2.0] 4 [2.5] 5 [2.4]
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 6
NTP Experiment-Test: 96020-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: CHRONIC WITH AVERAGE SEVERITY GRADES[b] Date: 03/03/04
Route: GAVAGE TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153) Time: 10:11:30
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 0 NG / 10 NG / 100 NG / 300 NG / 1000 NG/
0 UG 10 UG 100 UG 300 UG 1000 UG
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - CONT
Red Pulp, Atrophy 1 [2.0] 1 [2.0] 5 [2.2]
Thymus (53) (50) (48) (50) (51)
Atrophy 33 [2.3] 33 [2.5] 43 [2.8] 42 [3.8] 49 [3.6]
Cyst 1 [3.0]
Hemorrhage 1 [2.0] 3 [2.3] 1 [3.0]
Hyperplasia, Lymphoid 2 [2.5]
Inflammation 1 [3.0]
Epithelial Cell, Hyperplasia 1 [2.0]
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (53) (53) (52) (53) (52)
Cyst 3 [3.0] 2 [2.0] 2 [2.0] 3 [2.3] 1 [3.0]
Hyperplasia 29 [1.5] 29 [1.4] 25 [1.5] 22 [1.4] 3 [1.0]
Inflammation, Granulomatous 5 [2.0] 4 [2.3] 3 [1.7]
Duct, Cyst 1 [4.0]
Skin (53) (53) (53) (53) (53)
Angiectasis 1 [3.0]
Cyst Epithelial Inclusion 1
Fibrosis 1 [3.0]
Inflammation 1 [2.0] 1 [3.0]
Ulcer 2 [2.0] 1 [3.0]
Dermis, Fibrosis 1 [3.0]
Epidermis, Hyperplasia 1 [4.0]
Subcutaneous Tissue, Inflammation 1 [4.0]
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Skeletal Muscle (1) (1) (1) (1)
Hemorrhage 1 [3.0]
Inflammation 1 [3.0]
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (53) (53) (53) (52) (52)
Hemorrhage 1 [3.0] 1 [3.0]
Hydrocephalus 1 [2.0]
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 7
NTP Experiment-Test: 96020-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: CHRONIC WITH AVERAGE SEVERITY GRADES[b] Date: 03/03/04
Route: GAVAGE TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153) Time: 10:11:30
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 0 NG / 10 NG / 100 NG / 300 NG / 1000 NG/
0 UG 10 UG 100 UG 300 UG 1000 UG
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (53) (53) (52) (53) (52)
Hemorrhage 1 [2.0]
Infiltration Cellular, Histiocyte 47 [1.8] 41 [1.9] 47 [1.6] 46 [1.7] 45 [1.5]
Inflammation 8 [1.8] 5 [2.2] 2 [2.0] 4 [1.8] 1 [3.0]
Metaplasia, Squamous 1 [1.0] 2 [1.5] 11 [2.1]
Mineralization 1 [1.0] 1 [2.0]
Alveolar Epithelium, Hyperplasia 23 [1.2] 20 [1.4] 17 [1.1] 5 [1.4] 5 [1.4]
Alveolar Epithelium, Metaplasia, Bronchiolar 6 [1.5] 23 [1.4] 34 [1.7] 32 [1.9]
Bronchiole, Hyperplasia 1 [3.0]
Mediastinum, Hemorrhage 1 [3.0]
Mediastinum, Necrosis 1 [3.0]
Serosa, Inflammation 1 [2.0]
Nose (53) (53) (53) (53) (53)
Hyperplasia 1 [3.0]
Inflammation 22 [1.5] 13 [1.2] 13 [1.2] 13 [1.6] 31 [1.3]
Glands, Hyperplasia 8 [2.0]
Olfactory Epithelium, Degeneration 1 [2.0] 2 [2.0]
Olfactory Epithelium, Metaplasia 4 [2.3] 3 [2.0] 5 [2.0] 6 [2.2] 15 [2.2]
Respiratory Epithelium, Hyperplasia 10 [2.4] 5 [1.8] 7 [2.0] 11 [2.1] 20 [2.6]
Respiratory Epithelium, Metaplasia 1 [2.0]
Respiratory Epithelium, Vacuolization
Cytoplasmic 1 [2.0]
Trachea (53) (53) (52) (53) (52)
Inflammation 1 [1.0]
Peritracheal Tissue, Hemorrhage 1 [3.0]
Peritracheal Tissue, Inflammation 1 [3.0]
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Eye (53) (53) (53) (52) (52)
Anterior Chamber, Ciliary Body, Cornea,
Inflammation 1 [3.0] 3 [3.0]
Cornea, Inflammation 1 [3.0]
Retina, Atrophy 1 [2.0] 3 [2.0] 4 [2.3] 2 [2.0] 5 [2.2]
Harderian Gland (53) (53) (53) (52) (52)
Inflammation 20 [1.0] 14 [1.1] 16 [1.1] 14 [1.3] 16 [1.4]
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (53) (53) (52) (52) (51)
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 8
NTP Experiment-Test: 96020-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: CHRONIC WITH AVERAGE SEVERITY GRADES[b] Date: 03/03/04
Route: GAVAGE TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153) Time: 10:11:30
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 0 NG / 10 NG / 100 NG / 300 NG / 1000 NG/
0 UG 10 UG 100 UG 300 UG 1000 UG
____________________________________________________________________________________________________________________________________
URINARY SYSTEM - CONT
Accumulation, Hyaline Droplet 2 [2.0] 1 [1.0] 1 [2.0] 1 [1.0]
Calculus Gross Observation 1
Calculus Micro Observation Only 7 4 1 4 1
Casts Protein 2 [2.0] 1 [1.0]
Cyst 1 [3.0] 1 [2.0] 1 [3.0]
Infarct 1 [3.0] 1 [2.0]
Inflammation, Chronic Active 1 [2.0] 1 [2.0] 1 [3.0] 1 [3.0]
Inflammation, Suppurative 5 [1.2] 3 [1.3] 1 [1.0] 5 [1.0] 1 [2.0]
Mineralization 42 [1.0] 38 [1.1] 39 [1.0] 42 [1.0] 35 [1.0]
Necrosis 1 [1.0]
Nephropathy 29 [1.2] 22 [1.0] 29 [1.1] 34 [1.3] 43 [2.2]
Pigmentation 1 [2.0] 3 [1.0] 7 [1.3] 35 [2.0]
Pelvis, Dilatation 1 [2.0] 2 [2.5] 1 [3.0]
Pelvis, Inflammation 3 [2.0] 4 [1.8] 3 [2.3] 5 [1.8]
Renal Tubule, Degeneration 1 [3.0] 2 [2.0] 1 [3.0]
Transitional Epithelium, Hyperplasia 2 [2.0] 2 [1.0] 4 [1.8] 11 [1.9] 6 [2.2]
Ureter (1) (1) (1) (1)
Inflammation 1 [2.0] 1 [2.0]
Mineralization 1 [3.0]
Transitional Epithelium, Hyperplasia 1 [3.0] 1 [3.0]
Urinary Bladder (53) (53) (53) (52) (50)
Inflammation 7 [1.1] 8 [1.1] 5 [1.2] 7 [1.4]
Transitional Epithelium, Hyperplasia 1 [2.0]
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 9
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------